Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/226913
Evolución de biomarcadores de angiogénesis e inflamación en pacientes con telangiectasia hemorrágica hereditaria durante el tratamiento con bevacizumab: protocolo de estudio
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is a rare disease characterized by mucocutaneous telangiectasia and visceral vascular malformations. Treatment with bevacizumab is recommended in patients with liver involvement and high output cardiac failure (HOCF) or those with severe gastrointestinal (GI) involvement. However, there is no evidence on how to monitor such treatment using biomarkers. Material and methods: This is an exploratory, observational, prospective, single-center study carried out in an HHT referral unit. The inclusion period for the start of bevacizumab was from January 2022 to May 2023. Patients with an indication for starting bevacizumab were selected and underwent blood tests at baseline and during the induction (36 weeks) and maintenance phase in order to analyze 21 biomarkers related to angiogenesis and inflammation. In addition, control HHT patients without indication for bevacizumab and healthy controls matched 1:1:1 by age, sex, and genetic subtype (for HHT patients) underwent a baseline biomarker study. The main objective is to analyze the evolution of these biomarkers in patients with HHT treated with bevacizumab. As secondary objectives, baseline differences in the concentration of these biomarkers between the three groups and correlation with the hemoglobin levels will be analyzed. Groups description: During the study period, nine patients with an indication for bevacizumab were included, seven due to anemia of GI origin and two due to liver involvement with HOCF, with an overall mean age of 70 +/- 8.4 years, and subsequently the respective nine patients with HHT without bevacizumab and nine controls without HHT were selected. Conclusions: The results of this exploratory study will provide new knowledge regarding potential biomarkers for monitoring the response to treatment with bevacizumab. Furthermore, it could generate new hypotheses about the role of certain biomarkers at the pathophysiological, diagnostic, and therapeutic levels. (c) 2025 The Authors. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Subject
Subject (English)
Citation
Citation
VILLANUEVA, Bernat, et al. Evolución de biomarcadores de angiogénesis e inflamación en pacientes con telangiectasia hemorrágica hereditaria durante el tratamiento con bevacizumab: protocolo de estudio. Revista Clínica Española. 2025. Vol. 225, num. 9, pags. 502370. ISSN 0014-2565. [consulted: 8 of June of 2026]. Available at: https://hdl.handle.net/2445/226913